Health care reform will force payers in the United States to become much more focused on alleviating margin pressure—mainly by shifting medical costs and the risk associated with treatments to other stakeholders. Drug makers must find ways to absorb more of these burdens while still maintaining their own profitability, BCG’s Dirk Calcoen and Jon Kaplan explain in The RPM Report.
Our work and our people are regularly covered in publications around the world. More